Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.

Cancer treatment reports Pub Date : 1987-12-01
L Beex, J Burghouts, J van Turnhout, W Breed, H Hillen, A Holdrinet, G Boetius, G Hoogendoorn, W Doesburg, M Verhulst
{"title":"Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.","authors":"L Beex,&nbsp;J Burghouts,&nbsp;J van Turnhout,&nbsp;W Breed,&nbsp;H Hillen,&nbsp;A Holdrinet,&nbsp;G Boetius,&nbsp;G Hoogendoorn,&nbsp;W Doesburg,&nbsp;M Verhulst","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In a multicenter trial, 123 patients with advanced breast cancer who had been treated with tamoxifen and/or chemotherapy were randomized to receive medroxyprogesterone acetate (MPA) orally 300 mg X 3 daily or im 500 mg daily for 4 weeks and 500 mg X 2 weekly thereafter. All case histories were reviewed extramurally by the criteria of the International Union Against Cancer. Five and 11 patients were not eligible and evaluable for response, respectively. Pretreatment characteristics were well balanced in both treated groups. Twenty-five of all 107 (23%) evaluable patients achieved an objective remission, whereas in a further 15% the disease became stable after previous progression. Results in both treatment arms did not differ significantly. The median duration of objective remission was 12 and 14 months for orally and im treated patients, respectively (P greater than 0.10). No statistically significant differences in the survival times of orally and im treated patients were found. Pretreatment characteristics positively correlated with an objective remission during MPA therapy in both groups were age greater than 50 years (P less than 0.02) and no previous chemotherapy (P less than 0.01). Toxicity included an increase in body weight, cushingoid effects, muscle cramps, and tremors in both groups. In four patients on im therapy, local infections developed. Mean serum MPA levels reached values above 100 ng/ml in nine orally and eight im treated patients (P greater than 0.10), and neither differed significantly in the patients responding to or failing therapy. In both MPA arms, plasma cortisol levels were suppressed. The drop in plasma cortisol levels was more pronounced in patients with objective remissions than in patients who failed (P = 0.04). In conclusion, oral and im MPA in the given doses had similar activity. Im administration of MPA should be reserved for patients not able to take oral medication.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1987-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment reports","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In a multicenter trial, 123 patients with advanced breast cancer who had been treated with tamoxifen and/or chemotherapy were randomized to receive medroxyprogesterone acetate (MPA) orally 300 mg X 3 daily or im 500 mg daily for 4 weeks and 500 mg X 2 weekly thereafter. All case histories were reviewed extramurally by the criteria of the International Union Against Cancer. Five and 11 patients were not eligible and evaluable for response, respectively. Pretreatment characteristics were well balanced in both treated groups. Twenty-five of all 107 (23%) evaluable patients achieved an objective remission, whereas in a further 15% the disease became stable after previous progression. Results in both treatment arms did not differ significantly. The median duration of objective remission was 12 and 14 months for orally and im treated patients, respectively (P greater than 0.10). No statistically significant differences in the survival times of orally and im treated patients were found. Pretreatment characteristics positively correlated with an objective remission during MPA therapy in both groups were age greater than 50 years (P less than 0.02) and no previous chemotherapy (P less than 0.01). Toxicity included an increase in body weight, cushingoid effects, muscle cramps, and tremors in both groups. In four patients on im therapy, local infections developed. Mean serum MPA levels reached values above 100 ng/ml in nine orally and eight im treated patients (P greater than 0.10), and neither differed significantly in the patients responding to or failing therapy. In both MPA arms, plasma cortisol levels were suppressed. The drop in plasma cortisol levels was more pronounced in patients with objective remissions than in patients who failed (P = 0.04). In conclusion, oral and im MPA in the given doses had similar activity. Im administration of MPA should be reserved for patients not able to take oral medication.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
预治疗的晚期乳腺癌患者口服与静脉注射大剂量醋酸甲孕酮。
在一项多中心试验中,123例接受他莫昔芬和/或化疗的晚期乳腺癌患者随机接受醋酸甲孕酮(MPA),每日口服300 mg x3或每日服用500 mg,持续4周,此后每周服用500 mg x2。所有病例的历史都按照国际抗癌联盟的标准进行了外部审查。5例和11例患者分别不符合条件和无法评估反应。两个治疗组的预处理特征都很好地平衡。107例可评估患者中有25例(23%)实现了客观缓解,而另有15%的患者在既往进展后病情稳定。两个治疗组的结果没有显著差异。口服和非口服治疗患者客观缓解的中位持续时间分别为12个月和14个月(P > 0.10)。口服和注射治疗患者的生存时间无统计学差异。两组患者的预处理特征均为年龄大于50岁(P < 0.02)、无化疗史(P < 0.01),与MPA治疗期间客观缓解呈正相关。毒性包括两组体重增加、库欣类药物效应、肌肉痉挛和震颤。四名接受im治疗的患者出现了局部感染。9例口服和8例im治疗患者的平均血清MPA水平达到100 ng/ml以上(P大于0.10),在治疗有效或失败的患者中没有显着差异。在两个MPA组中,血浆皮质醇水平均受到抑制。客观缓解的患者血浆皮质醇水平的下降比治疗失败的患者更为明显(P = 0.04)。综上所述,口服和口服MPA在一定剂量下具有相似的活性。对于不能口服药物的患者,应保留给药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Phase II trial of fludarabine phosphate in patients with head and neck cancer: a Southwest Oncology Group Study. Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group Study. Identification of new drugs in small cell lung cancer: phase II agents first?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1